Authors:
Bengala, C
Pazzagli, I
Innocenti, F
Donati, S
Favre, C
Menconi, MC
Greco, F
Danesi, R
Orlandini, C
Guarneri, V
Del Tacca, M
Conte, PF
Citation: C. Bengala et al., High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), ANN ONCOL, 12(1), 2001, pp. 69-74
Authors:
Conte, P
Gennari, A
Guarneri, V
Landucci, E
Donati, S
Salvadori, B
Bengala, C
Orlandini, C
Baldini, E
Citation: P. Conte et al., Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials, ONCOLOGY-NY, 15(5), 2001, pp. 21-23
Authors:
Consolini, R
Calleri, A
Bengala, C
Legitimo, A
Conte, PF
Citation: R. Consolini et al., Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34(+) cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support, HAEMATOLOG, 86(9), 2001, pp. 959-964
Authors:
Conte, PF
Gennari, A
Donati, S
Salvadori, B
Baldini, E
Bengala, C
Pazzagli, I
Orlandini, C
Danesi, R
Fogli, S
Del Tacca, M
Citation: Pf. Conte et al., Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study, BREAST CANC, 68(2), 2001, pp. 171-179
Authors:
Michelotti, A
Venturini, M
Tibaldi, C
Bengala, C
Gallo, L
Carnino, F
Del Mastro, L
Lionetto, R
Montanaro, E
Rosso, R
Conte, P
Citation: A. Michelotti et al., Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients, BREAST CANC, 59(2), 2000, pp. 133-139
Authors:
Gennari, A
Salvadori, B
Donati, S
Bengala, C
Orlandini, C
Danesi, R
Del Tacca, M
Bruzzi, P
Conte, PF
Citation: A. Gennari et al., Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors, J CL ONCOL, 17(11), 1999, pp. 3596-3602
Citation: C. Bengala et Pf. Conte, Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma - Reply, CANCER, 85(10), 1999, pp. 2296-2296